{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:53:41Z","timestamp":1776228821573,"version":"3.50.1"},"reference-count":72,"publisher":"American Psychiatric Association Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FOC"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1176\/appi.focus.20250042","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:00:19Z","timestamp":1776225619000},"page":"179-187","source":"Crossref","is-referenced-by-count":0,"title":["Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management"],"prefix":"10.1176","volume":"24","author":[{"given":"Cody","family":"Olson","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern, Dallas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene Maria","family":"Gir\u00f3n Bravo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern, Dallas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern, Dallas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Elizabeth","family":"Camp","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern, Dallas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-230376"},{"key":"e_1_3_2_3_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2022","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text rev. Washington, DC, American Psychiatric Association, 2022","edition":"5"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.5414\/NP301204"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-022-01347-y"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-47802-4_21"},{"key":"e_1_3_2_7_2","first-page":"3111","volume-title":"Tasman\u2019s Psychiatry","author":"Sher Y","year":"2024","unstructured":"Sher Y, Maldonado JR: Neurocognitive disorders; in Tasman\u2019s Psychiatry, 5th ed. Cham, Springer, 2024, pp 3111\u20133169","edition":"5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-15401-0_13"},{"key":"e_1_3_2_9_2","first-page":"88","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"18","author":"Livingston G","year":"2019","unstructured":"Livingston G, Huntley J, Sommerlad A, et al: Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet Neurol 2019; 18:88\u2013106","journal-title":"Lancet Neurol"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1585711"},{"key":"e_1_3_2_11_2","unstructured":"Alzheimer\u2019s Association: 2025 Alzheimer\u2019s Disease Facts and Figures 2025. https:\/\/www.alz.org\/getmedia\/ef8f48f9-ad36-48ea-87f9-b74034635c1e\/alzheimers-facts-and-figures.pdf"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00038-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.13931"},{"key":"e_1_3_2_14_2","volume-title":"StatPearls","author":"Emmady PD","year":"2025","unstructured":"Emmady PD, Schoo C, Tadi P: Major neurocognitive disorder (dementia); in StatPearls. Treasure Island, FL, StatPearls Publishing, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557444"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.4782"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.23"},{"key":"e_1_3_2_17_2","volume-title":"StatPearls","author":"Cloak N","year":"2025","unstructured":"Cloak N, Schoo C, Al Khalili Y: Behavioral and psychological symptoms in dementia; in StatPearls. Treasure Island, FL, StatPearls Publishing, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551552"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Lee HH Chinnameyyappan A Feldman OJ et al: Behavioral and psychological symptoms (BPSD) in Alzheimer\u2019s disease (AD): development and treatment. Curr Top Behav Neurosci 2025; 69:245\u2013273","DOI":"10.1007\/7854_2024_566"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001503"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013128"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.89.7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb00232.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00093-5"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.00310.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-815854-8.00029-X"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1445"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt7"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2389.2003.51306.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2022.2032601"},{"key":"e_1_3_2_34_2","first-page":"CD013306","article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis","volume":"2","author":"Battle CE","year":"2021","unstructured":"Battle CE, Abdul-Rahim AH, Shenkin SD, et al: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2021; 2:CD013306","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23557"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000113034"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421140-00003"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000231744.69631.33"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050151"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12798"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00019-2"},{"key":"e_1_3_2_42_2","first-page":"367","article-title":"Memantine: a review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias","volume":"4","author":"Thomas SJ","year":"2009","unstructured":"Thomas SJ, Grossberg GT: Memantine: a review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias. Clin Interv Aging 2009; 4:367\u2013377","journal-title":"Clin Interv Aging"},{"key":"e_1_3_2_43_2","first-page":"CD003154","article-title":"Memantine for dementia","volume":"3","author":"McShane R","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, et al: Memantine for dementia. Cochrane Database Syst Rev 2019; 3:CD003154","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.317"},{"key":"e_1_3_2_45_2","first-page":"303","article-title":"Donepezil in Alzheimer\u2019s disease: from conventional trials to pharmacogenetics","volume":"3","author":"Cacabelos R","year":"2007","unstructured":"Cacabelos R: Donepezil in Alzheimer\u2019s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 2007; 3:303\u2013333","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.747"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_2_50_2","article-title":"Biogen abandons aducanumab, pivots focus to lecanemab for Alzheimer disease.","author":"Joszt L","year":"2024","unstructured":"Joszt L: Biogen abandons aducanumab, pivots focus to lecanemab for Alzheimer disease. Am J Manag Care Jan 31 2024. https:\/\/www.ajmc.com\/view\/biogen-abandons-aducanumab-pivots-focus-to-lecanemab-for-alzheimer-disease","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.01.012"},{"key":"e_1_3_2_54_2","first-page":"e12452","article-title":"Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia","volume":"10","author":"Ward M","year":"2024","unstructured":"Ward M, Carter LP, Huang JY, et al: Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia. Alzheimers Dement 2024; 10:e12452","journal-title":"Alzheimers Dement"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1687"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-231266"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001501"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200127"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S371641"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.173501"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11030347"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018"},{"key":"e_1_3_2_63_2","volume-title":"Celexa (Citalopram) Prescribing information","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration: Celexa (Citalopram) Prescribing information. Silver Spring, MD: U.S. Food and Drug Administration, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020822"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01210-1"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2021.04.014"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113641"},{"key":"e_1_3_2_67_2","first-page":"24nr03737","article-title":"A review of dextromethorphan-quinidine for the treatment of agitation in dementia","volume":"26","author":"Khan AN","year":"2024","unstructured":"Khan AN, Murphy KS, Tampi RR: A review of dextromethorphan-quinidine for the treatment of agitation in dementia. Prim Care Companion CNS Disord 2024; 26:24nr03737","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_2_68_2","first-page":"2022","article-title":"Prazosin for the management of behavioural and psychological symptoms of dementia","volume":"11","author":"Tampi RR","year":"2022","unstructured":"Tampi RR, Tampi DJ, Farheen SA, et al: Prazosin for the management of behavioural and psychological symptoms of dementia. Drugs Context 2022; 11:2022\u20132028","journal-title":"Drugs Context"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.078457"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610223000091"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1017\/S104161022300039X"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2262-7837"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241258473"}],"container-title":["Focus"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:01:09Z","timestamp":1776225669000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.focus.20250042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1176\/appi.focus.20250042"],"URL":"https:\/\/doi.org\/10.1176\/appi.focus.20250042","relation":{},"ISSN":["1541-4094","1541-4108"],"issn-type":[{"value":"1541-4094","type":"print"},{"value":"1541-4108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}